Updates
** Shares of CSL CSL.AX rise as much as 3.1% to A$249.17, hitting its highest level since May 30
** Stock marks largest intraday pct. gain since mid May
** Biotech giant says it plans to trim its research and development division across six global locations
** Co to also rely more on external partnerships, eyeing a reduction of its internal workforce
** CSL did not provide details on the job reductions in its emailed statement to Reuters
** We are streamlining the R&D organisation to foster collaboration, reduce duplication and improve efficiencies and we are simplifying our operating model - CSL spokesperson
** Co's statement comes a day after the Australian Financial Review reported CSL may cut around one-third of its 2,500 R&D staff
** Stock down 11.8% YTD, including the day's moves
(Reporting by Nichiket Sunil and Nikita Maria Jino in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.